title: Influence of fibrate treatment on malondialdehyde-modified LDL concentration.
abstract: BACKGROUND
  Drug therapy is considered essential to the clinical prevention of atherosclerotic lesions in patients with diabetes mellitus (DM).
  
  
  METHODS
  To confirm the effects of fibrate therapy, we determined low-density lipoprotein (LDL) size by gradient gel electrophoresis and malondialdehyde-modified LDL (MDA-LDL) concentrations by enzyme-linked immunosolvent assay (ELISA) and clarified the association between apolipoprotein B (apo B) and MDA-LDL during the fibrate therapy.
  
  
  RESULTS
  Mean MDA-LDL concentrations were higher in healthy men than in healthy women. There were no significant differences in mean MDA-LDL concentrations between age groups for males or females. According to the regression equation (y = 0.063x + 10.9) obtained for apo B and MDA-LDL concentrations with fibrate treatment, the apo B concentration in those may need to be decreased to 1260 mg/l to restore the MDA-LDL concentration to the control concentration (65 +/- 25 units/l). This slope of the apoB/MDA-LDL regression line was approximately half of that with no-drug treatment (y = 0.109x - 10.8).
  
  
  CONCLUSIONS
  Fibrate therapy had an effect on reducing serum MDA-LDL concentration in diabetic patients.
authors.affiliation: Diagnostics Research Laboratories, Daiichi Pure Chemicals Co., 3-1, Kôyodai 3-Chome, Ryugasaki, Ibaraki 301-0852, Japan.
authors.forename: Akira
authors.initials: A
authors.lastname: Kondo
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Morita
authors.forename: Hirotoshi
authors.initials: H
authors.lastname: Nakamura
authors.forename: Kazuo
authors.initials: K
authors.lastname: Kotani
authors.forename: Kiichiro
authors.initials: K
authors.lastname: Kobori
authors.forename: Sachiko
authors.initials: S
authors.lastname: Ito
authors.forename: Mitsuhisa
authors.initials: M
authors.lastname: Manabe
authors.forename: Kazunori
authors.initials: K
authors.lastname: Saito
authors.forename: Takashi
authors.initials: T
authors.lastname: Kanno
authors.forename: Masato
authors.initials: M
authors.lastname: Maekawa
mesh_terms: D000328:Adult; D000375:Aging; D001055:Apolipoproteins B / Q000097:blood; D001161:Arteriosclerosis / Q000097:blood / Q000150:complications / Q000378:metabolism / Q000517:prevention & control; D001629:Bezafibrate / Q000494:pharmacology*; D048909:Diabetes Complications; D003920:Diabetes Mellitus / Q000097:blood* / Q000378:metabolism* / Q000628:therapy; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D006801:Humans; D008077:Lipoproteins, LDL / Q000097:blood* / Q000737:chemistry / Q000187:drug effects / Q000378:metabolism*; D008297:Male; D008315:Malondialdehyde / Q000737:chemistry*; D008875:Middle Aged; D012727:Sex Characteristics
chemical_list: D001055:Apolipoproteins B; D008077:Lipoproteins, LDL; D008315:Malondialdehyde; D001629:Bezafibrate